Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 10/14/25 → 10/14/27 |
Funding
- Basilea Pharmaceutica International Ltd Allschwil: $2.00
FORWARD FMGX-CS-302: An Interventional Phase 3, Open-Label, Two-Cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients with Invasive Mold Infections Caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucora
- Greenberg, Richard (PI)
- Simmons, Christopher (CoI)